Table 2.
Precision of the NARCOMS ordinary least squares mapping equation applied to data from study DER-401a
| Model | MAE (SD) | RMSE |
|---|---|---|
| NARCOMS cohort8 | ||
| Overall EQ-5D-3L (n=3,505) | 0.109 (0.096) | 0.145 |
| EQ-5D-3L <0.50 (n=438; 12.5%) | 0.297 (0.094) | 0.312 |
| EQ-5D-3L 0.50–<0.75 (n=867; 24.7%) | 0.063 (0.054) | 0.083 |
| EQ-5D-3L ≥0.75 (n=2,200; 62.8%) | 0.089 (0.060) | 0.107 |
| DER-401 at baseline9 | ||
| Overall EQ-5D-3L (n=429) | 0.116 (0.103) | 0.155 |
| EQ-5D-3L <0.50 (n=59; 13.8%) | 0.313 (0.098) | 0.328 |
| EQ-5D-3L 0.50–<0.75 (n=147; 34.3%) | 0.063 (0.048) | 0.080 |
| EQ-5D-3L ≥0.75 (n=223; 51.9%) | 0.099 (0.062) | 0.116 |
| DER-401 at week 49 | ||
| Overall EQ-5D-3L (n=398) | 0.105 (0.090) | 0.138 |
| EQ-5D-3L <0.50 (n=40; 10.0%) | 0.295 (0.080) | 0.305 |
| EQ-5D-3L 0.50–<0.75 (n=136; 34.2%) | 0.081 (0.065) | 0.104 |
| EQ-5D-3L ≥0.75 (n=222; 55.8%) | 0.085 (0.058) | 0.104 |
Notes:
a
Mapping model is EQ-5D-3L =+0.002× (item 1), −0.009× (item 2), −0.01× (item 3), −0.029× (item 4), −0.019× (item 5), −0.0000881× (item 6), −0.008× (item 7), −0.002× (item 8), +0.013× (item 9), −0.011× (item 10), +0.001× (item 11), −0.008× (item 12), and +0.983 (constant).
Abbreviations: NARCOMS, North American Research Committee on Multiple Sclerosis; DER, dalfampridine extended release; EQ-5D-3L, EuroQol 5-dimension 3-level version; MAE, mean absolute error; RMSE, root-mean-square error; SD, standard deviation.